Positive breast cancer is prone to recurrence. There is a type of breast cancer that spreads fast, has high malignancy, has poor prognosis and is prone to recurrence and metastasis, and the median survival of patients is only about 3 years, it is HER2-positive breast cancer, which accounts for about 20-30% of patients. Unfortunately, nearly half of the breast cancer patients have not been tested for HER2 before treatment or the test is not standardized, that is, patients simply do not know whether they are HER2-positive breast cancer or not, and deciding the treatment plan without knowing the subtype is likely to result in over-treatment or unreasonable treatment, which affects the survival of patients. HER2 positive breast cancer is not difficult to understand, that is, in breast cancer treatment is divided into “negative” and “positive”, HER2 positive is the overexpression of human epidermal growth factor receptor 2, which means it is activated and stimulates cancer cells to proliferate like crazy, so this type of This means that it is activated and stimulates the cancer cells to proliferate like crazy, therefore, this type of breast cancer patients have high malignancy, fast progression and poor chemotherapy effect. In fact, HER2 testing is not a very complicated technique, the most common immunohistochemistry method can be performed in level II or above hospitals for only 80 ~100 RMB per test and is covered by medical insurance. The reason why HER2 testing is emphasized and reminded is that there is a “gold standard” treatment plan for this type of tumor, that is, for early stage breast cancer patients, in addition to conventional radiotherapy and chemotherapy, Herceptin treatment should be given for 1 year after surgery. The current data show that this treatment regimen reduces the risk of recurrence of breast cancer by 52% and the risk of death by 33%. In advanced breast cancer, Herceptin combined with chemotherapy can extend patient survival by 8-10 months compared to chemotherapy alone. For this testing problem, on the one hand, clinicians do not know and pay enough attention to HER2-positive breast cancer, and on the other hand, patients are reminded to actively communicate with their doctors about the test results and ask repeatedly if they do not understand. In addition, it is important to consult not only the doctors in oncology hospitals, but also try to find medical oncologists, who are relatively more experienced.